Skip to content

Radiomics Model for the Diagnosis of Pneumocystis Jirovecii Pneumonia in Non-HIV Patients

Radiomics Model for the Diagnosis of Pneumocystis Jirovecii Pneumonia in Non-HIV Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05701631
Enrollment
140
Registered
2023-01-27
Start date
2023-01-15
Completion date
2023-06-30
Last updated
2023-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis Jirovecii Pneumonia

Keywords

Computed tomography, Diagnostic tests, Pneumocystis jirovecii pneumonia, Radiomics

Brief summary

To evaluate the performance of radiomics in differentiating Pneumocystis jirovecii pneumonia (PCP) from other types of pneumonia and to improve the diagnostic efficacy of non-invasive tests in non-HIV patients.

Detailed description

Retrospective study, including non-HIV patients hospitalized for suspected PCP from January 2010 to December 2022. The included patients were randomized in a 7:3 ratio into training and validation cohorts. Radiomic features were extracted from semi-automatically identified infected areas in computed tomography (CT) scans and used to construct a radiomic model, which was then compared to a clinical-imaging model built with clinical and semantic CT features in terms of diagnostic performance of PCP. The combination of the radiomic model and serum β-D-glucan levels was also evaluated for PCP diagnosis.

Interventions

DIAGNOSTIC_TESTRadiomic model

Radiomic model for PCP diagnosis

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* aged over eighteen years; * presence of an underlying disease known to be associated with PCP * symptoms of lower respiratory tract infection, such as fever, cough or dyspnea * signs of lung infection on high resolution CT at the on-set of the disease * received BAL examination within three days after CT scans * underwent qPCR and IF staining tests on the BAL fluid sample.

Exclusion criteria

* with HIV infection * taking trimethoprim-sulfamethoxazole for prophylaxis * undiagnosed by qPCR and IF staining tests

Design outcomes

Primary

MeasureTime frameDescription
the diagnostic performance of radiomic model in the PCP diagnosis6 monthsThe included patients were randomized in a 7:3 ratio into training and validation cohorts. Radiomic features were extracted from semi-automatically identified infected areas in computed tomography (CT) scans and used to construct a radiomic model. Then, the area under the curve (AUC) of the receiver operating characteristic (ROC) curves were calculated and used to evaluate the diagnostic performance (accuracy, sensitivity, specialty, positive predictive value, negative predictive value) of the model for PCP diagnosis in both training and validation cohorts.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026